- Market Capitalization, $K 209,873
- Shares Outstanding, K 55,522
- Annual Sales, $ 31,560 K
- Annual Income, $ -33,320 K
- 60-Month Beta 1.16
- Price/Sales 6.53
- Price/Cash Flow N/A
- Price/Book 9.82
|Period||Period Low||Period High||Performance|
| || |
-0.65 (-14.14%)since 05/24/19
| || |
-0.03 (-0.74%)since 03/26/19
| || |
+0.11 (+2.89%)since 06/26/18
ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru Niagen(R) (nicotinamide riboside) received the 'Ingredient of the Year: Healthy Aging' award at the NutraIngredients-USA...
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20 Annual B. Riley FBR Investor Conference at the...
ChromaDex (CDXC) delivered earnings and revenue surprises of 0.00% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million -
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement. The transaction was led by international...
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2019....
ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN(R) with Vancouver-based WELL Health Technologies Corp. (TSX.V: WELL) who intends on distributing TRU NIAGEN(R)...
ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen...
ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen(R))...
ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world's foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will...